EUVIMEDEUVIMED entdecken
Crossref

The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer

Teruhisa Sakamoto, Mikiya Kishino, Yuki Murakami, Kozo Miyatani, Takehiko Hanaki, Yuji Shishido, Kyoichi Kihara, Tomoyuki Matsunaga, Manabu Yamamoto, Naruo Tokuyasu, Yoshiyuki Fujiwara

Surgery Today · 2024

DOI: 10.1007/s00595-024-02877-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Surgery Today, 2024. Verfasst von Teruhisa Sakamoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, 36-1 Nichi-Cho, Yonago, 683-8504,…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Cachexia, Neoplasm Recurrence, Local, Pancreatectomy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Cancer cachexia leads to poor outcomes, especially for patients with advanced stage disease. The cachexia index (CXI), a novel biomarker for cancer cachexia, has been identified as a prognostic indicator for several malignancies. The present study aimed to clarify the prognostic significance of the CXI for patients with recurrent pancreatic cancer. METHODS: This retrospective study enrolled 113 patients diagnosed with recurrence following pancreatectomy for pancreatic cancer, to analyze the association between the CXI and prognostic survival. RESULTS: The 2-year overall survival rate and median survival of all patients were 28.5% and 12.6 months, respectively. The 2-year overall survival curve in the high CXI group was significantly better than that in the low CXI group (p < 0.001). The rate of chemotherapy after recurrence was significantly lower in the low CXI group than in the high CXI group (p = 0.002). Multivariate analysis identified the CXI as an independent prognostic factor for patients with recurrent pancreatic cancer (p = 0.011). CONCLUSIONS: The CXI proved useful for predicting the post-recurrence prognosis of patients with recurrent pancreatic cancer. Patients with a low CXI at the time of recurrence have poorer prognostic outcomes than those with a high CXI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCachexiaNeoplasm Recurrence, LocalPancreatectomyHumansMaleFemalePrognosisAgedRetrospective StudiesMiddle AgedSurvival RateAged, 80 and overAdult

Stichwörter der Autor:innen

CXIPancreatic cancerRecurrence

Autor:innen und Institutionen

  • Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, 36-1 Nichi-Cho, Yonago, 683-8504, Japan. tesakamo@tottori-u.ac.jp.
  • Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, Faculty of Medicine, Tottori University, 36-1 Nichi-Cho, Yonago, 683-8504, Japan.

Zitieren

APA

Sakamoto, T., Kishino, M., Murakami, Y., Miyatani, K., Hanaki, T., Shishido, Y., Kihara, K., Matsunaga, T., Yamamoto, M., Tokuyasu, N., & Fujiwara, Y. (2024). The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer. Surgery Today. https://doi.org/10.1007/s00595-024-02877-z

Vancouver

Sakamoto T, Kishino M, Murakami Y, Miyatani K, Hanaki T, Shishido Y, et al. The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer. Surgery Today. 2024. doi:10.1007/s00595-024-02877-z

BibTeX
@article{Sakamoto2024,
  author = {Sakamoto, Teruhisa and Kishino, Mikiya and Murakami, Yuki and Miyatani, Kozo and Hanaki, Takehiko and Shishido, Yuji and Kihara, Kyoichi and Matsunaga, Tomoyuki and Yamamoto, Manabu and Tokuyasu, Naruo and Fujiwara, Yoshiyuki},
  title = {The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer},
  journal = {Surgery Today},
  year = {2024},
  doi = {10.1007/s00595-024-02877-z}
}
Kostenlos starten →